Metabolism Drugs Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-12　·　160 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 14.8 Bn
2033 年預估規模: USD 18.21 Bn
年複合成長率 CAGR: 8.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-12頁數 160報告編號 CMI1955

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Metabolism Drugs Market, By Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others), By Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

Metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are meant to. Metabolic disorders occur due to buildup of proteins, lipids, glycogen, urea, calcium stones, and toxic substances among others. Each of these molecules have certain designated metabolic pathways, and metabolic agents (enzymes, proteins) at work. Inability of these agents to carry out their tasks cause buildup of the molecules in the blood and other places. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease. Market Dynamics Increasing inorganic growth activities such as collaborations and agreement among market players is expected to drive the market growth over the forecast period. For instance, on December 10, 2021, Eli Lilly and Company, a pharmaceutical company and Regor Therapeutics Group, a biotechnology company announced multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. According to this agreement, Eli Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan. Furthermore, market players are increasingly focusing on clinical trials for development of enzyme replacement therapy. For instance, on June 16, 2020, Sanofi, a global biopharmaceutical company announced the results for investigational enzyme replacement therapy (ERT), avalglucosidase alfa that showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD), according to results from the Phase 3 trial. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD. Key features of the study • This report provides an in-depth analysis of the global metabolism drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global metabolism drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global metabolism drugs market Market Segmentation • By Therapy Type o Enzyme Replacement Therapy o Substrate Reduction Therapy o Small Molecule Drugs o Others • By Application o Glycogen Metabolism Disease o Lipid Metabolism Disease o Amino Acid Metabolism Disease o Others • By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Regional Insights o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Merck & Co., Inc. o Novartis AG o Amicus Therapeutics o AstraZeneca Plc o Boehringer Ingelheim o Shire Plc o Sanofi Genzyme o BioMarin Pharmaceutical, Inc. o Horizon Pharma Plc o GlaxoSmithKline Plc.

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Therapy Type  Market Snippet, By Application  Market Snippet, By Distribution Channel  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  PEST Analysis  PORTER’s Five Forces Analysis  Market Opportunities  Regulatory Scenario  Key Developments  Industry Trend 4. Global Metabolism Drugs Market, By Therapy Type, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Enzyme Replacement Therapy  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Substrate Reduction Therapy  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Small Molecule Drugs  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Others  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends 5. Global Metabolism Drugs Market, By Application, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Glycogen Metabolism Disease  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Lipid Metabolism Disease  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Amino Acid Metabolism Disease  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Others  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 6. Global Metabolism Drugs Market, By Distribution Channel, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 - 2033  Segment Trends o Hospital Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Retail Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Online Pharmacies  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 7. Global Metabolism Drugs Market, By Region, 2026-2033, (USD Bn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Region, 2021 - 2033 o North America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Application, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o U.S. o Canada o Latin America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Application, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Application, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Application, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Application, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033  Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)  Market Size and Forecast, By Application, 2026- 2033, (USD Bn)  Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)  Market Size and Forecast, By Country, 2026- 2033, (USD Bn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Heat Map Analysis o Market Share Analysis (3x3 Matrix) o Company Profiles  Merck & Co., Inc. o Company Overview o Product Type Portfolio o Recent Developments/Updates  Novartis AG o Company Overview o Product Type Portfolio o Recent Developments/Updates  Amicus Therapeutics o Company Overview o Product Type Portfolio o Recent Developments/Updates  AstraZeneca Plc o Company Overview o Product Type Portfolio o Recent Developments/Updates  Boehringer Ingelheim o Company Overview o Product Type Portfolio o Recent Developments/Updates  Shire Plc o Company Overview o Product Type Portfolio o Recent Developments/Updates  Sanofi Genzyme o Company Overview o Product Type Portfolio o Recent Developments/Updates  BioMarin Pharmaceutical, Inc. o Company Overview o Product Type Portfolio o Recent Developments/Updates  Horizon Pharma Plc. o Company Overview o Product Type Portfolio o Recent Developments/Updates  GlaxoSmithKline Plc. o Company Overview o Product Type Portfolio o Recent Developments/Updates 9. Analyst Recommendation o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. Section o References o Research Methodology o About Us and Sales Contact

提及公司

Merck & Co., Inc.Novartis AGAmicus TherapeuticsAstraZeneca PlcBoehringer IngelheimShire PlcSanofi GenzymeBioMarin Pharmaceutical, Inc.Horizon Pharma PlcGlaxoSmithKline Plc.

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們